Drug reference

enasidenib

IDH2 inhibitor · Antineoplastic agent

IDH2 inhibitorAntineoplastic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactions

BerotralstatSevereDatabaseDDInter
RosuvastatinSevereDatabaseDDInter

Mechanism

Enasidenib is an orally bioavailable IDH2 inhibitor.

Indications

relapsed or refractory AML with an IDH2 mutation

Side effects

Serious

differentiation syndrome (can be fatal)

Pregnancy & lactation

Pregnancy

Drug interactions

Berotralstat

Severe

Database

Drug interaction classified as: absorption

Source: DDInter

Rosuvastatin

Severe

Database

Clinical effect not specified

Source: DDInter

10 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.

Related guidelines

Heart failure in diabetes

RSSDI · Cardiology · 2023

Hypertension in adults

ICMR · Cardiology · 2019

Hypertrophic cardiomyopathy

ESC · Cardiology · 2026

Diabetes management in chronic kidney disease

KDIGO · Nephrology · 2022

Type 2 diabetes in adults

NICE · Endocrinology · 2022

Ask House about enasidenib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10